Expected to grow in the coming months, the clinico-genomic database is the first of several products that Foundation Medicine and Flatiron plan to co-develop using a comprehensive, HIPAA-compliant information platform. The two companies are exploring partnerships within the broader research and academic communities to accelerate utilization of this clinico-genomic database for novel drug development and clinical trial applications.ABOUT FLATIRON HEALTH Flatiron Health is a healthcare technology company harnessing the power of real-world data to accelerate research and improve cancer care. The company works with healthcare providers, life sciences organizations and academic centers to collect, aggregate and analyze data for over 1.5 million active cancer patients. Today, over 250 cancer clinics and 10 of the top 12 life science companies are using Flatiron's platforms. Flatiron is backed by Google Ventures, First Round Capital, Roche and others. For more information, please visit http://flatiron.com or follow Flatiron on Twitter (@flatironhealth). Flatiron Health ® is a registered trademark of Flatiron Health, Inc. ABOUT FOUNDATION MEDICINE Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG). Foundation Medicine ® , FoundationOne ® and FoundationOne ® Heme are registered trademarks and FoundationACT™ is a trademark of Foundation Medicine, Inc. Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the implementation of the collaboration between Foundation Medicine and Flatiron, the ability Foundation Medicine and Flatiron to grow the database, the utility of the clinico-genomic database, and the ability of the clinico-genomic database to effectively support the research requirements of researchers and biopharmaceutical companies involved in drug development and clinical trials. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the collaboration is not implemented or is not implemented as quickly or as fully as anticipated; Flatiron is not able to gain access to sufficient amounts of clinical information and Foundation Medicine is not able to generate sufficient amounts of genomic data to create a robust and successful product; the clinico-genomic database does not perform as expected or is not widely adopted or used by researchers; the clinico-genomic database is not financially sustainable; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine and Flatiron undertake no duty to update this information unless required by law.